Möchten Sie immer auf dem neuesten Stand bleiben?

New York, USA, April 09, 2026 (GLOBE NEWSWIRE) -- Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight The...

STUDIO CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- As this year’s Myeloma Action Month came to a close, the International Myeloma Foundation (IMF) was truly grateful for the incredible support...

Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Biopharmaceutical CXO Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The Biopharmaceutical CXO...

New York, USA, April 08, 2026 (GLOBE NEWSWIRE) -- Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of...

ASSEMBLÉE GÉNÉRALE MIXTE DU 29 AVRIL 2026 MODALITÉS DE MISE À DISPOSITION OU DE CONSULTATION DES DOCUMENTS PRÉPARATOIRES Les actionnaires de la Société sont invités à participer à l’assemblée...

  COMBINED GENERAL MEETING OF APRIL 29, 2026 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday April 29,...

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306...

MELBOURNE, Australia and OXFORD, United Kingdom, April 08, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for...

New York, USA, April 07, 2026 (GLOBE NEWSWIRE) -- Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight |...

BRISBANE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...